Healthcare Industry News: joint replacement
News Release - February 28, 2008
Biomet Inc. Appoints Jon Serbousek as President of Orthopedics DivisionWARSAW, Ind.--(HSMN NewsFeed)--Biomet, Inc. announces the appointment of Jon Serbousek as the President of Biomet Orthopedics, Inc., effective March 3rd. In this role, Jon will lead Biomet’s efforts in continuing the success and growth of the U.S. total joint reconstruction business.
During the past eight years, Jon has held diverse general management roles with Medtronic in the areas of Spinal Reconstruction, International, New Technology Development and most recently, worldwide Vice-President and General Manager, Biologics. Prior to Medtronic, Jon spent 13 years with DePuy, holding positions of Vice President of Marketing and Product Development Joint Reconstruction, Vice President, Spinal Operations; Vice President and General Manager, Arthroscopy & Sports Medicine and a series of Product Development and Engineering Management positions.
Jeff Binder, President and CEO of Biomet, stated, “I have worked closely with Jon in the past and he fits perfectly with Biomet’s culture and heritage. He shares our company’s commitment to clinical excellence and innovation, extraordinary service, personalized patient care and surgeon prominence in the healthcare system.”
“I am very excited about joining the Biomet team,” Serbousek said. “The company’s track record of innovation, clinical performance, and growth is unmatched, and I am honored to have the opportunity to contribute to its future.”
Biomet, Inc. and its subsidiaries design, manufacture, and market products used primarily by musculoskeletal medical specialists in both surgical and non-surgical therapy. Biomet’s product portfolio encompasses reconstructive products, including orthopedic joint replacement devices, bone cements and accessories, autologous therapies and dental reconstructive implants; fixation products, including electrical bone growth stimulators, internal and external orthopedic fixation devices, craniomaxillofacial implants and bone substitute materials; spinal products, including spinal stimulation devices, spinal hardware and orthobiologics; and other products, such as arthroscopy products and softgoods and bracing products. Headquartered in Warsaw, Indiana, Biomet and its subsidiaries currently distribute products in more than 70 countries.
This press release contains certain statements that are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements are qualified by the inherent risks and uncertainties surrounding future expectations generally, and also may materially differ from actual future experience involving any one or more of such statements. Such risks and uncertainties include our ability to develop and market new products and technologies in a timely manner, and the risk factors as set forth from time to time in Biomet’s filings with the SEC. The inclusion of a forward-looking statement herein should not be regarded as a representation by Biomet that Biomet’s objectives will be achieved. Biomet undertakes no obligation to publicly update forward-looking statements, whether as a result of new information, future events or otherwise.
Source: Biomet, Inc
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.